Dedicated mobile application for drug adverse reaction reporting by patients with relapsing remitting multiple sclerosis (Vigip-SEP study): study protocol for a randomized controlled trial

BACKGROUND: The reporting of adverse drug reactions (ADR) by patients represents an interesting challenge in the field of pharmacovigilance, but the reporting system is not adequately implemented in France. In 2015, only 20 MS patients in France reported ADR due to first-line disease-modifying drugs...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Trials
Main Authors: Defer, Gilles, Le Caignec, Florian, Fedrizzi, Sophie, Montastruc, François, Chevanne, Damien, Parienti, Jean-Jacques, Peyro-Saint-Paul, Laure
Formato: Artigo
Idioma:Inglês
Publicado em: BioMed Central 2018
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5845183/
https://ncbi.nlm.nih.gov/pubmed/29523169
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13063-018-2560-4
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados